COPD exacerbations: defining their cause and prevention

Lancet

Volumn 370, Issue 9589, 2007, Pages 786-796

  Wedzicha, Jadwiga A ^a   Seemungal, Terence AR ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BACTERIUM LYSATE; CILOMILAST; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INFLIXIMAB; IPRATROPIUM BROMIDE; PLACEBO; PNEUMOCOCCUS VACCINE; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; HOME CARE; HOME OXYGEN THERAPY; HUMAN; LONG TERM CARE; PATHOPHYSIOLOGY; POLLUTION; PRIORITY JOURNAL; PULMONARY REHABILITATION; REVIEW; SELF CARE; VIRUS INFECTION;

EID: 34548290964     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61382-8     Document Type: Review

References (125)

1. Seemungal T., Donaldson G., Paul E., Bestall J., Jeffries D., and Wedzicha J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 151 (1998) 1418-1422
2. British Thoracic Society. Burden of Lung Disease Report, 2nd edn 2006. http://www.brit-thoracic.org.uk/copd/pubs_frameset.html (accessed May 2, 2007).
3. Seemungal T., Donaldson G., Bhowmik A., Jeffries D., and Wedzicha J. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 1608-1613
4. Roberts C., Lowe D., Bucknall C., Ryland I., Kelly Y., and Pearson M. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 57 (2002) 137-141
5. Perera W., Hurst J., Wilkinson T., et al. Inflammatory changes and recurrence at COPD exacerbations. Eur Respir J 29 (2007) 527-534
6. Rabe K., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of COPD-2006 Update. Am J Respir Crit Care Med (2007). published online May 16. DOI: 10.1164/rccm.200703-456SO
7. Rodriguez-Roisin R. Towards a consensus definition for COPD exacerbations. Chest 117 (2000) 398S-401S
8. Hurst J., Perera W., Wilkinson T., Donaldson G., and Wedzicha J. Utility of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 (2006) 867-874
9. Bhowmik A., Seemungal T., Sapsford R., and Wedzicha J. Relation of sputum inflammatory markers to symptoms and physiological changes at COPD exacerbations. Thorax 55 (2000) 114-200
10. Saetta M., Di Stefano A., Maestrelli P., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150 (1994) 1646-1652
11. Qiu Y., Zhu J., Bandi V., et al. Biopsy neutrophilia, neutrophil chemokin and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168 (2003) 968-975
12. Drost E., Skwarski K., Sauleda K., et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 60 (2005) 293-300
13. Hurst J., Perera W., Wilkinson T., Donaldson G., and Wedzicha J. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 (2006) 71-78
14. Hogg J., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2645-2653
15. Biernacki W., Kharitonov S., and Barnes P. Increased leukotriene B4 and 8-isprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 58 (2003) 294-298
16. Hurst J., Wilkinson T., Perera W., Donaldson G., and Wedzicha J. Relationships among bacteria, upper airway, lower Airway, and systemic inflammation in COPD. Chest 127 (2005) 1219-1226
17. Wedzicha J., Seemungal T., MacCallum P., et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemostasis 84 (2000) 210-215
18. Smeeth L., Thomas S., Hall A., Hubbard R., Farrington P., and Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351 (2004) 2611-2618
19. O'Donnell D., and Parker C. COPD exacerbations. 3: Pathophysiology. Thorax 61 (2006) 354-361
20. Bhowmik A., Seemungal T., Donaldson G., and Wedzicha J. Effects of exacerbations and seasonality on exhaled nitric oxide In COPD. Eur Respir J 26 (2005) 1009-1015
21. Stevenson N., Walker P., Costello R., and Calverley P. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 1510-1516
22. Johnson M., Birch M., Carter R., Kinsella J., and Stevenson R. Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry. Thorax 62 (2007) 299-306
23. Sapey E., and Stockley R. COPD exacerbations. 2: Aetiology. Thorax 61 (2006) 250-258
24. Donaldson G., Seemungal T., Jeffries D., and Wedzicha J. Effect of environmental temperature on symptoms, lung function and mortality in COPD patients. Eur Respir J 13 (1999) 844-849
25. Hurst J., Donaldson G., Wilkinson T., Perera W., and Wedzicha J. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 26 (2005) 846-852
26. Seemungal T., Harper-Owen R., Bhowmik A., Jeffries D., and Wedzicha J. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 16 (2000) 677-683
27. Seemungal T., Harper-Owen R., Bhowmik A., et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 1618-1623
28. Rohde G., Wiethege A., Borg I., et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 58 (2003) 37-42
29. Tan W., Xiang X., Qiu D., Ng T., Lam S., and Hegele R. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 1154 (2003) 272-277
30. Ko F., Ip M., Chan P., et al. Viral etiology of acute exacerbations of chronic obstructive pulmonary disease in Hong Kong. Chest (2007). published online June 15. DOI: 10.1378/chest.07-0530
31. Falsey A., Formica M., Hennessey P., et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 (2006) 639-643
32. 1 decline in patients with COPD. Am J Respir Crit Care Med 173 (2006) 871-876
33. Retmales I., Elliott M., Meshi B., et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 164 (2001) 469-473
34. Mallia P., Message S., Kebadze T., Parker H., Kon O., and Johnston S. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res 7 (2006) 116
35. Greenberg S., Allen M., Wilson J., and Atmar R. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162 (2000) 167-173
36. Sapey E., and Stockley R. COPD exacerbations. 2: Aetiology. Thorax 61 (2006) 250-258
37. Wilkinson T., Hurst J., Perera W., Wilks M., Donaldson G., and Wedzicha J. Interactions between lower airway bacterial and rhinoviral infection at exacerbations of chronic obstructive pulmonary disease. Chest 129 (2006) 317-324
38. Stockley R., O'Brien C., Pye A., et al. Relationship to sputum colour to nature and out-patient management of acute exacerbations of COPD. Chest 117 (2000) 1638-1645
39. Soler N., Agustí C., Angrill J., De la Bellacasa J., and Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 62 (2007) 29-35
40. Anthonisen N., Manfreda J., Warren C., Hershfield E., Harding G., and Nelson N. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-220
41. Ram F., Rodriguez-Roisin R., Granados-Navarrete A., Garcia-Aymerich J., and Barnes N. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2 (2006) CD004403.
42. Sethi S., Evans N., Grant B., and Murphy T. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347 (2002) 465-471
43. Yi K., Sethi S., and Murphy T. Human immune response to nontypeable Hameophilus influenzae in chronic bronchitis. J Infect Dis 176 (1997) 1247-1252
44. Papi A., Bellettato C., Braccioni F., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 173 (2006) 1114-1121
45. Mogulkoc N., Karakurt S., Isalska B., et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 160 (1999) 349-353
46. Blasi F., Damato S., Consentini R., et al. C Pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 57 (2002) 672-676
47. Seemungal T., Wedzicha J., MacCallum P., Johnston S., and Lambert P. C Pneumoniae and COPD exacerbation. Thorax 57 (2002) 1087-1088
48. Lieberman D., Lieberman D., Shmarkov O., et al. Serological evidence of Legionella species infection in acute exacerbations of COPD. Eur Respir J 19 (2002) 392-397
49. Diederen B., Van der Walk P., Kluytmans J., Peeters M., and Hendrix R. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J 30 (2007) 240-244
50. Anderson H., Limb E., Bland J., Ponce de Leon A., Strachan D., and Bower J. Health effects of an air pollution episode in London, December 1991. Thorax 50 (1995) 1188-1193
51. Anderson H., Spix C., Medina S., et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 10 (1997) 1064-1071
52. Yang C., and Chen C. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a subtropical city: Taipei, Taiwan. J Toxicol Environ Health A 70 (2007) 1214-1229
53. Gouveia N., de Freitas C., Martins L., and Marcilio I. Respiratory and cardiovascular hospitalizations associated with air pollution in the city of Sao Paulo, Brazil. Cad Saude Publica 22 (2006) 2669-2677
54. Linaker C., Coggon D., Holgate S., et al. Personal exposure to nitrogen dioxide and risk of airflow obstruction in asthmatic children with upper respiratory infection. Thorax 55 (2000) 930-933
55. Ko F., Tam W., Chan D., et al. The temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. Thorax (2007). published online Feb 20. DOI: 10.1136/thx.2006.076166
56. Burge S., and Wedzicha J. COPD exacerbations: definitions and classifications. Eur Respir J 41 (2003) 46s-53s
57. Garcia-Aymerich J., Farrero E., Félez M., Izquierdo J., Marrades R., and Antó J. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58 (2003) 100-105
58. Soler-Cataluna J., Martinez-Garcia M., Roman Sanchez P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005) 925-931
59. Fletcher C., Peto R., Tinker C., et al. The natural history of chronic bronchitis and emphysema (1976), Oxford University Press, Oxford
60. 1 decline in current smokers but not ex-smokers with mild chronic obstructive lung disease: results from the Lung Health Study. Am J Respir Crit Care Med 164 (2001) 358-364
61. Donaldson G., Seemungal T., Bhowmik A., and Wedzicha J. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
62. Roberts C., Lowe D., Bucknall C., Ryland I., Kelly Y., and Pearson M. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 57 (2002) 137-141
63. Donaldson G., Seemungal T., Patel I., et al. Airway and Systemic inflammation and decline in lung function, in chronic obstructive pulmonary disease. Chest 128 (2005) 1995-2004
64. Spruit M., Gosselink R., Troosters T., et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 58 (2003) 752-756
65. Pitta F., Troosters T., Probst V., Spruit M., Decramer M., and Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest 129 (2006) 536-544
66. Donaldson G., Wilkinson T., Hurst J., Perera W., and Wedzicha J. Exacerbations, and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (2005) 446-452
67. Holguin F., Folch E., Redd S., and Mannino D. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128 (2005) 2005-2011
68. Baker E., Janaway C., Philips B., et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61 (2006) 284-289
69. Winter J., Buckier P., Bautista A., et al. Frequency of venous thrombosis in patients with exacerbation of chronic obstructive lung disease. Thorax 38 (1983) 605-608
70. Erelel M., Cuhadarogiu C., Ece T., and Arseven O. The frequency of deep venous thormobosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 96 (2002) 515-518
71. Tillie-Leblond I., Marquette C.-H., Perez T., et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 144 (2006) 390-396
72. Smeeth L., Cook C., Thomas S., Hall A., Hubbard R., and Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367 (2006) 1075-1079
73. Rutschmann O., Cornuz J., Poletti P.-A., et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease?. Thorax 62 (2007) 121-125
74. Burge P., Calverley P., Jones P., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to sever chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
75. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
76. Vincken W., van Noord J., and Greefhorst A. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
77. Casaburi R., Mahler D., Jones P., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
78. Nichol K., Baken L., and Nelson A. Relation between influenza vaccination and out patient visits, hospitalisation and mortality in elderly patients with chronic lung disease. Ann Intern Med 130 (1999) 397-403
79. Gorse G., O'Connor T., Young S., et al. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 130 (2006) 1109-1116
80. Wongsurakiat P., Maranetra K., Wasi C., Kositanont U., Dejsomritrutai W., and Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 25 (2004) 1971-1972
81. Wang C., Wang S., Lai C., Lin L., and Chou P. Impact of influenza vaccination on major cause-specific mortality. Vaccine 26 (2007) 1196-1203
82. Granger R., Walters J., Poole P., et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4 (2006) CD001390.
83. Alfageme I., Vazquez R., Reyes N., et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61 (2006) 189-195
84. Collet J., Shapiro S., Ernst P., et al. Effect of an immunostimulating agent on acute exacerbations and hospitalization in COPD patients. Am J Respir Crit Care Med 156 (1997) 1719-1724
85. Soler M., Mutterlein R., Cozma G., and Swiss-German OM-85 Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 74 (2007) 26-32
86. Sprenkle M., Niewoehner D., MacDonald R., Rutks I., and Wilt T. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD 2 (2005) 167-175
87. Niewoehner D., Erbland M., Deupree R., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340 (1999) 1941-1947
88. Davies L., Angus R., and Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354 (1999) 456-460
89. Jones P., Willits L., Burge P., and Calverley P. The influence of disease severity and the effect of fluticasone propionate on COPD exacerbations in the ISOLDE study. Eur Respir J 21 (2003) 68-73
90. The Lung Health Study research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. NEJM 343 (2000) 1902-1909
91. Mahler D., Donohue J., Barbee R., et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115 (1999) 957-965
92. Rennard S., Anderson W., ZuWallack R., et al. Use of long-acting inhaled beta2 adrenergic agonist salmeterol xinafoate in patients with COPD. Am J Respir Crit Care Med 163 (2001) 1087-1092
93. Calverley P., Anderson J., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
94. Van Noord J., de Munck D., Bantje T., et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 15 (2000) 878-885
95. Rossi A., Kristufek P., Levine B., et al. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral slow-release theophylline in treatment of COPD. Chest 121 (2002) 1058-1069
96. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
97. Calverley P., Boonsawat W., Cseke Z., et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-918
98. Whelan C., Johnson M., and Vardey C. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 110 (1993) 613-618
99. Barnes P. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 104 suppl (1999) S10-S17
100. Niewoehner D., Rice K., Cote C., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once daily inhaled anticholinergic bronchodilator: a randomised trial. Ann Intern Med 143 (2005) 317-326
101. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on inflammation and exacerbations in chronic obstructive pulmonary disease Eur Respir J (in press).
102. Aaron S., Vandemheen K., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146 (2007) 545-555
103. Zhou Y., Wang X., Zeng X., et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 11 (2006) 603-610
104. Rennard S., Schachter N., Strek M., Rickard K., and Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129 (2006) 56-66
105. Rabe K., Bateman E., O'Donnell D., Witte S., Bredenbröker D., and Bethke T. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366 (2005) 563-571
106. Calverley P., Sanchez Toril F., McIvor A., Teichmann P., Bredenbroeker P., and Fabbri L. Effect of one year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (2007) 154-161
107. Rennard S., Fogarty C., Kelsen S., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 926-934
108. Decramer M., Rutten van-Molken M., Dekhuijzen P., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS). Lancet 365 (2005) 1552-1560
109. Poole P., and Black P. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 (2006) CD001287.
110. Hogg J., Chu F., Tan W., et al. Survival following lung volume reduction in COPD: insights from small airway pathology. Am J Respir Crit Care Med (2007). published online June 7. DOI: 10.1164/rccm.200612-1772OC
111. Hill A., Campbell E., Hill S., Bayley D., and Stockley R. Association between airway bacterial load and markers of airway inflammation in patients with chronic bronchitis. Am J Med 109 (2000) 288-295
112. Patel I., Seemungal T., Wilks M., Lloyd Owen S., Donaldson G., and Wedzicha J. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 57 (2002) 759-764
113. Scott C., Walker P., and Calverley P. COPD exacerbations. 4: Prevention. Thorax 61 (2006) 440-447
114. Griffiths T., Burr M., Campbell I., et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation. Lancet 355 (2000) 362-368
115. Wilkinson T., Donaldson G., Hurst J., Seemungal T., and Wedzicha J. Impact of reporting and early therapy on outcome of exacerbations of COPD. Am J Respir Crit Care Med 169 (2004) 1298-1303
116. Garcia-Aymerich J., Farrero E., Félez M., Izquierdo J., Marrades R., Antó J., and for the Estudi del Factors de Risc d'Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58 (2003) 100-105
117. Bourbeau J., Julien M., Maltais F., et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 163 (2003) 585-591
118. Taylor S., Candy B., Bryar R., et al. Effectiveness of nursing and nurse-led chronic disease management innovations for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ 331 (2005) 485
119. Casas A., Troosters T., Garcia-Aymerich J., et al. Integrated care prevents hospitalisations for exacerbations in COPD. Eur Respir J 28 (2006) 123-130
120. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet i (1981) 681-686
121. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease. Ann Intern Med 93 (1980) 391-398
122. Okubadejo A., Paul E., Jones P., and Wedzicha J. Does long term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia?. Eur Respir J 9 (1996) 2335-2339
123. Ringbaek T., Viskum K., and Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease?. Eur Respir J 20 (2002) 38-42
124. Meecham Jones D., Paul E., Jones P., and Wedzicha J. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD: a randomised controlled study. Am J Respir Crit Care Med 152 (1995) 538-544
125. Casanova C., Celli B., Tost L., et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 118 (2000) 1582-1590